Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,619.00
  • Today's Change-13.00 / -0.36%
  • Shares traded91.20k
  • 1 Year change-3.36%
  • Beta0.5471
Data delayed at least 20 minutes, as of Jun 08 2023 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.

  • Revenue in JPY (TTM)72.98bn
  • Net income in JPY5.44bn
  • Incorporated1948
  • Employees1.16k
  • Location
    Kaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
  • Phone+81 359775001
  • Fax+81 359775131
  • Websitehttps://www.kaken.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Towa Pharmaceutical Co Ltd208.86bn2.20bn91.60bn4.08k40.330.63934.240.438644.0944.094,219.212,781.160.59381.643.97--0.62584.730.86346.3934.8141.
Shin Nippon Biomedical Laboratories Ltd25.09bn6.06bn94.42bn994.0015.583.6012.343.76145.57145.57602.69629.610.51972.066.12--12.539.4719.5614.3452.0050.0024.1224.390.7886--0.415819.1141.378.61-14.98--37.23--
Torii Pharmaceutical Co Ltd49.75bn2.77bn101.23bn563.0035.600.843731.302.0398.7398.731,770.514,166.290.38432.642.3088,360,570.002.146.352.347.2447.4750.375.5716.186.68--0.0020.834.06-5.2816.89-3.52-18.6615.81
Kyorin Pharmaceutical Co Ltd113.27bn4.72bn111.58bn2.22k20.950.788813.030.985182.4282.421,976.682,189.400.6511.402.65--2.723.203.363.9344.2948.724.175.102.03--0.14567.807.330.47120.12-6.4019.42-2.16
ispace Inc989.24m-11.40bn125.60bn220.00------126.96-211.47-211.4718.35-43.55----------------55.88---1,152.22--1.36-97.841.53--46.74---180.75------
Mochida Pharmaceutical Co Ltd103.26bn6.65bn128.40bn1.54k18.760.96113.781.24177.78177.782,778.763,470.180.64142.033.47--4.134.865.025.9453.3752.206.447.363.41----41.67-6.28-0.6644-37.09-5.9214.62-1.21
Zeria Pharmaceutical Co Ltd68.38bn6.20bn130.30bn1.74k17.501.6510.551.91140.14140.141,548.071,484.790.52741.534.14--4.793.377.415.4072.3771.459.086.520.75156.270.429441.0314.871.1556.418.305.403.30
Sawai Group Holdings Co Ltd200.34bn12.67bn145.30bn2.97k11.490.72064.760.7253288.73288.734,567.634,604.670.56151.473.03--3.601.144.951.5631.2636.926.412.241.2287.950.255880.413.373.58144.81-2.0110.060.00
Kissei Pharmaceutical Co Ltd67.49bn10.53bn149.73bn1.83k12.660.687310.162.22228.30228.301,463.584,204.650.29391.682.96--4.633.215.023.4747.9752.3915.7611.105.20--0.007636.533.23-1.83-18.523.083.7410.76
KAKEN PHARMACEUTICAL CO., LTD.72.98bn5.44bn166.85bn1.16k25.160.998920.842.29144.37144.371,942.573,636.170.44032.193.69--
JCR Pharmaceuticals Co Ltd34.34bn3.77bn178.77bn816.0045.703.3030.915.2130.1630.16275.36418.050.35760.53612.57--3.949.636.6614.6774.1374.3411.0319.320.819--0.303126.30-32.7710.77-74.004.2053.6725.21
Takara Bio Inc78.14bn16.01bn201.82bn1.67k12.601.809.752.58132.97132.97648.94931.930.63811.905.29--13.1111.7815.0913.3657.2963.9020.5420.224.6210,270.500.008624.1415.4319.32-19.3346.9729.8756.32
Tsumura & Co140.04bn16.48bn218.22bn3.92k13.190.86177.791.56215.57215.571,832.133,299.430.37460.7382.49--4.654.985.646.0348.7653.8212.4112.743.53--0.226430.978.103.51-12.502.596.410.00
Sosei Group Corp15.39bn1.05bn248.25bn202.00272.074.24103.0116.1311.0811.08185.73710.590.1582--11.8676,202,970.001.08--1.14--95.26--6.82----28.290.3392---12.10---62.44------
Data as of Jun 08 2023. Currency figures normalised to Kaken Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

18.28%Per cent of shares held by top holders
HolderShares% Held
Silchester International Investors LLPas of 25 Mar 20223.69m8.03%
Nomura Asset Management Co., Ltd.as of 28 Apr 20231.16m2.52%
The Vanguard Group, Inc.as of 05 May 2023853.23k1.86%
Norges Bank Investment Managementas of 31 Dec 2022521.47k1.14%
Daiwa Asset Management Co. Ltd.as of 31 Mar 2023501.50k1.09%
Nikko Asset Management Co., Ltd.as of 02 May 2023500.90k1.09%
BlackRock Fund Advisorsas of 04 May 2023398.10k0.87%
Dimensional Fund Advisors LPas of 04 May 2023307.94k0.67%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 01 May 2023271.60k0.59%
Brandes Investment Partners LPas of 01 Jun 2023196.60k0.43%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.